Skip to main content


Latest articles

20-05-2022 | Diabetes | News | Article

Survival time analysis shows CV benefits of GLP1 receptor agonists

Glucagon-like peptide-1 receptor agonists may delay the incidence of major adverse cardiovascular events by an average of 0.6 months over a 4-year period in people with type 2 diabetes, meta-analysis data suggest.

19-05-2022 | Diabetes | News | Article

Semaglutide offers alternative to prandial insulin in type 2 diabetes

Adding a weekly semaglutide injection in people already using basal insulin to treat type 2 diabetes avoids the need for prandial insulin, show the SUSTAIN 11 findings.

18-05-2022 | Diabetes | News | Article

Pros and cons with empagliflozin addition to closed-loop insulin

Adding daily empagliflozin to closed-loop insulin delivery improves time in range but also increases ketone levels in people with type 1 diabetes, shows a randomized trial.

16-05-2022 | Diabetes | News | Article

Tirzepatide gets nod from US FDA

Click through to read more on this announcement

13-05-2022 | Diabetes | News | Article

Clinical criteria can identify insulin allergy

Researchers have identified four simple clinical criteria that can be used to predict the likelihood of insulin allergy and guide decisions about the need for confirmatory allergy testing.

13-05-2022 | Diabetes | News | Article

DAWN: Support for dorzagliatin–metformin combination therapy in type 2 diabetes

People with type 2 diabetes who have suboptimal glycemic control on metformin alone may benefit from add-on treatment with the dual-acting glucokinase activator dorzagliatin, report the DAWN investigators.

12-05-2022 | Diabetes | News | Article

Study shows potential for type 2 diabetes characteristics to guide management

Research published in Nature Medicine shows how the specific characteristics of people with type 2 diabetes could one day guide disease management.

09-05-2022 | Diabetes | News | Article

Ethnic-specific cutoffs proposed for type 2 diabetes screening

Researchers recommend using different BMI or age thresholds for type 2 diabetes screening in ethnic minority groups, on finding that a single threshold may miss many cases in non-White Americans.

09-05-2022 | Diabetes | News | Article

Bodyweight rebounds after semaglutide withdrawal

People who lose weight while taking semaglutide 2.4 mg regain two-thirds of what they lost during the first year after stopping the medication, shows the STEP 1 extension study.

06-05-2022 | Diabetes | News | Article

Renal prognosis improvements stalled in type 1 diabetes

The risk for kidney disease has fallen for people diagnosed with type 1 diabetes in more recent decades, but is still substantial and has stopped decreasing, study results suggest.

06-05-2022 | Diabetes | News | Article

Transdermal capillary blood sampling could simplify C-peptide measurement

Transdermal capillary blood collection produces samples in which C-peptide can be reliably measured, removing the need for venous blood sampling, report researchers.

05-05-2022 | Diabetes | News | Article

Diabetes treatment goal attainment ‘suboptimal’ in India

Less than 10% of people with self-reported diabetes in India meet optimal treatment targets for glycated hemoglobin, blood pressure, and low-density lipoprotein cholesterol control combined, show data from the ICMR-INDIAB study.

04-05-2022 | Diabetes | News | Article

Real-world study probes artificial pancreas system differences

Italian researchers have compared outcomes of children and adults with type 1 diabetes using Medtronic MiniMed 780G and the Tandem Control IQ closed-loop insulin delivery systems in real-world practice.

29-04-2022 | Diabetes | News | Article

Concentrated rapid-acting insulin shows early promise

Results of a phase 1 study show that a concentrated version of insulin aspart not only provides a smaller injection volume but also has a more rapid onset of action than the standard version.

29-04-2022 | Diabetes | News | Article

Most sensor-detected hypoglycemia goes unnoticed by people with diabetes

Early findings from the Hypo-METRICS trial indicate that people with diabetes are unaware on most of the occasions that their blood glucose dips into the hypoglycemic range.

29-04-2022 | Diabetes | News | Article

Poor glucose control risks SARS-CoV-2 infection despite immunization in type 2 diabetes

Poor glycemic control is associated with an impaired immune response to vaccination against SARS-CoV-2 and an increased risk for breakthrough infections in people with type 2 diabetes, report researchers.

28-04-2022 | Diabetes | News | Article

Mechanisms underlying tirzepatide efficacy revealed

Tirzepatide improves glucose control more than semaglutide in people with type 2 diabetes by improving beta-cell function as well as boosting insulin sensitivity and reducing glucagon secretion, shows a randomized trial.

28-04-2022 | Diabetes | News | Article

Kidney function abnormalities linked to increased stroke risk in type 2 diabetes

Study findings published in BMC Medicine show that increasing albuminuria, decreasing estimated glomerular filtration rate, and worsening stages of chronic kidney disease are independently associated with increased risk for stroke in people with type 2 diabetes.

27-04-2022 | Diabetes | News | Article

Tirzepatide reduces liver fat, improves time in range

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

26-04-2022 | Diabetes | News | Article

Subcutaneous insulin protocol feasible for DKA

Implementing a subcutaneous insulin protocol for the treatment of diabetic ketoacidosis significantly reduces intensive care admissions and readmission to hospital within 30 days of discharge without increasing hypoglycemia, research shows.